CIBI: Continuous Intrathecal Baclofen Infusion for Chronic Spasticity
Study Details
Study Description
Brief Summary
The purpose of this clinical investigation is to demonstrate product performance of the Prometra Programmable Pump System in the delivery of intrathecal Lioresal® (baclofen) for the management of severe spasticity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer. Lioresal Intrathecal (baclofen) is indicated for use in the management of severe spasticity. Spasticity is a major problem that has long challenged traditional medical treatment. While the incidence of spasticity is not known with certainty, it likely affects over half a million people in the United States and over 12 million worldwide. Spasticity is associated with some very common neurological disorders such as: multiple sclerosis, stroke, cerebral palsy, spinal cord and brain injuries. Chronic spasticity seriously restricts normal daily activities and reduces the quality of life for many patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Spasticity. Baclofen This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin. |
Device: Prometra Programmable Implantable Pump System
The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
|
Outcome Measures
Primary Outcome Measures
- The primary endpoint is: A change in the average lower extremity spasticity score as measured by the Modified Ashworth Scale [3 months]
Secondary Outcome Measures
- Secondary Endpoints include: Change in overall spasm frequency as measured by the Penn Spasm Frequency Scale. Change in overall Quality of Life as measured by the SF 36 and PSQI. SAE-free survival. DRAE-free survival. Tabulation of device complications. [3 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
The overall goal of this study is to choose patients most likely to experience therapeutic success while reducing the likelihood of risks, complications and adverse events.
Patients meeting all of the following criteria will be eligible for enrollment in the study:
- Patient with a history of severe chronic spastic hypertonia in the lower extremities lasting at least 6 months who:
-
fail to respond to maximum recommended doses of antispasmodic medications including baclofen, or
-
those who experience intolerable CNS side effects at effective oral doses
-
Patient is >21 years of age
-
Patient, or legally authorized representative (LAR), has provided written informed consent to participate in the study
-
Investigator considers the patient willing and able to fulfill all study requirements
-
Investigator has documented attempts to eliminate factors that can contribute to an increase in spasticity (e.g. infection)
-
Patient has had a successful trial of Lioresal® for the management of the target spasticity.
Exclusion Criteria:
Patients meeting any of the following criteria are to be excluded from the study:
-
Patient has MRI of the spine documenting structural abnormality preventing adequate CSF flow. (If the patient has a medical condition that contraindicates screening MRI, the investigator should proceed with the closest appropriate study i.e. CT scan, X-ray, to rule out any spinal abnormalities that would prevent intrathecal drug administration.)
-
Patient's anatomy is not large enough to accommodate the pump's size and weight.
-
Patient has a systemic infection.
-
Patient has renal insufficiency as evidenced by a baseline serum creatinine of >2.0 mg/dl.
-
Patient has a history of a bleeding disorder.
-
Patient has a history of blood clots such as deep vein thrombosis (DVT) or pulmonary embolism (PE) within 1 year of enrollment.
-
Patient is pregnant or breast-feeding, or is of child-bearing potential and not employing effective birth control.
-
Patient has known allergies or sensitivities to pump system materials (e.g., silicone rubber, titanium, polyphenylsulfone, acetal resin, polyvinylidene fluoride, tungsten).
-
Patient has known allergies to Lioresal® (baclofen), or would be contraindicated for Lioresal® based on the drug labeling.
-
Patient has other implantable electronic cardiac devices (i.e. pacemaker, defibrillator, CRT system)
-
Patient has an occupation where he/she would be exposed to high current industrial equipment, powerful magnets or transmitting towers, such as, electricians, electrical engineers or MRI technicians.
-
Patient is participating in another clinical trial.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Flowonix Medical
Investigators
- Principal Investigator: Robert Levy, MD, PhD, Northwestern University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- G090276